Metraipolis › archive › dc_e5eb7d972098
Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East — Europe PMC PMID:41346973
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41346973
- DOI
- 10.1093/crocol/otaf062
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T14:57:40.668Z
- SHA-256 of the archived text
0ca6d7d6385b740143ee8b6895a238b74690bc50c5b2ec6f4da8cea299160b01- Stable URL of this page
https://metraipolis.com/documento/dc_e5eb7d972098
How to cite
Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East — Europe PMC PMID:41346973 — Europe PMC (en), https://europepmc.org/article/MED/41346973 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e5eb7d972098 (Metraipolis archive dc_e5eb7d972098, sha256 0ca6d7d6385b740143ee8b6895a238b74690bc50c5b2ec6f4da8cea299160b01)
BibTeX
@misc{dce5eb7d972098,
title = {Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East — Europe PMC PMID:41346973},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41346973},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e5eb7d972098; sha256 0ca6d7d6385b740143ee8b6895a238b74690bc50c5b2ec6f4da8cea299160b01},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41346973. Agents can read the archived copy with the MCP tool read_document.